JP2016515537A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016515537A5 JP2016515537A5 JP2016503457A JP2016503457A JP2016515537A5 JP 2016515537 A5 JP2016515537 A5 JP 2016515537A5 JP 2016503457 A JP2016503457 A JP 2016503457A JP 2016503457 A JP2016503457 A JP 2016503457A JP 2016515537 A5 JP2016515537 A5 JP 2016515537A5
- Authority
- JP
- Japan
- Prior art keywords
- kinase
- cancer
- disease
- receptor
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 25
- 201000011510 cancer Diseases 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 208000009956 adenocarcinoma Diseases 0.000 claims description 12
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims description 11
- 210000004027 cell Anatomy 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 206010025323 Lymphomas Diseases 0.000 claims description 10
- 208000030507 AIDS Diseases 0.000 claims description 7
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 6
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 6
- 208000015114 central nervous system disease Diseases 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 206010006895 Cachexia Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 201000004624 Dermatitis Diseases 0.000 claims description 4
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 4
- 206010019280 Heart failures Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 102100037805 Mitogen-activated protein kinase 7 Human genes 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 206010063837 Reperfusion injury Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 208000010125 myocardial infarction Diseases 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010005949 Bone cancer Diseases 0.000 claims description 2
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims description 2
- 208000031886 HIV Infections Diseases 0.000 claims description 2
- 208000037357 HIV infectious disease Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 206010020751 Hypersensitivity Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010061218 Inflammation Diseases 0.000 claims description 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 2
- 206010062038 Lip neoplasm Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010027476 Metastases Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000001388 Opportunistic Infections Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 201000010001 Silicosis Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 208000007536 Thrombosis Diseases 0.000 claims description 2
- 208000025865 Ulcer Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 2
- 230000002917 arthritic effect Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 2
- 208000019664 bone resorption disease Diseases 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 208000037828 epithelial carcinoma Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005917 gastric ulcer Diseases 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000006721 lip cancer Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 210000002418 meninge Anatomy 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 208000013465 muscle pain Diseases 0.000 claims description 2
- 230000009826 neoplastic cell growth Effects 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 241001529453 unidentified herpesvirus Species 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 8
- 102000020233 phosphotransferase Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010001513 AIDS related complex Diseases 0.000 claims 2
- 102100036409 Activated CDC42 kinase 1 Human genes 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 101710104889 Cell division control protein 42 Proteins 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 102100039683 Cyclin-G-associated kinase Human genes 0.000 claims 2
- 101710113457 Cyclin-G-associated kinase Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 101710116743 Ephrin type-A receptor 2 Proteins 0.000 claims 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 2
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 2
- 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims 2
- 101000928956 Homo sapiens Activated CDC42 kinase 1 Proteins 0.000 claims 2
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 claims 2
- 101001051723 Homo sapiens Ribosomal protein S6 kinase alpha-6 Proteins 0.000 claims 2
- 101001026870 Homo sapiens Serine/threonine-protein kinase D1 Proteins 0.000 claims 2
- 108700027650 Mitogen-Activated Protein Kinase 7 Proteins 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 claims 2
- 108091008606 PDGF receptors Proteins 0.000 claims 2
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 2
- 108091008611 Protein Kinase B Proteins 0.000 claims 2
- 102100039810 Protein-tyrosine kinase 6 Human genes 0.000 claims 2
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims 2
- 102100024897 Ribosomal protein S6 kinase alpha-6 Human genes 0.000 claims 2
- 102100037310 Serine/threonine-protein kinase D1 Human genes 0.000 claims 2
- 102100039758 Serine/threonine-protein kinase DCLK1 Human genes 0.000 claims 2
- 102100039775 Serine/threonine-protein kinase DCLK2 Human genes 0.000 claims 2
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims 2
- 102100039987 Serine/threonine-protein kinase ULK2 Human genes 0.000 claims 2
- 101710203717 Serine/threonine-protein kinase ULK2 Proteins 0.000 claims 2
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 2
- 101710098624 Tyrosine-protein kinase ABL1 Proteins 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 108010056274 polo-like kinase 1 Proteins 0.000 claims 2
- 108060006633 protein kinase Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 claims 1
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 claims 1
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims 1
- 208000023706 Bruton agammaglobulinaemia Diseases 0.000 claims 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 1
- 241000282472 Canis lupus familiaris Species 0.000 claims 1
- 108010019243 Checkpoint Kinase 2 Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 claims 1
- 101000970023 Homo sapiens NUAK family SNF1-like kinase 1 Proteins 0.000 claims 1
- 101000686031 Homo sapiens Proto-oncogene tyrosine-protein kinase ROS Proteins 0.000 claims 1
- 101001026885 Homo sapiens Serine/threonine-protein kinase D3 Proteins 0.000 claims 1
- 101000885321 Homo sapiens Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims 1
- 101000885387 Homo sapiens Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims 1
- 101000601460 Homo sapiens Serine/threonine-protein kinase Nek4 Proteins 0.000 claims 1
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 claims 1
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 claims 1
- 101000582914 Homo sapiens Serine/threonine-protein kinase PLK4 Proteins 0.000 claims 1
- 101000838596 Homo sapiens Serine/threonine-protein kinase TAO3 Proteins 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 101150117329 NTRK3 gene Proteins 0.000 claims 1
- 102100021732 NUAK family SNF1-like kinase 1 Human genes 0.000 claims 1
- 101150056950 Ntrk2 gene Proteins 0.000 claims 1
- 108030005449 Polo kinases Proteins 0.000 claims 1
- 108010003506 Protein Kinase D2 Proteins 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 101710094328 Protein-tyrosine kinase 6 Proteins 0.000 claims 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 claims 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 claims 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims 1
- 102100023347 Proto-oncogene tyrosine-protein kinase ROS Human genes 0.000 claims 1
- 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 claims 1
- 101150071831 RPS6KA1 gene Proteins 0.000 claims 1
- 108091005682 Receptor kinases Proteins 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 claims 1
- 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 claims 1
- 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 claims 1
- 101710119197 Ribosomal protein S6 kinase alpha-1 Proteins 0.000 claims 1
- 108060006706 SRC Proteins 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 102100037312 Serine/threonine-protein kinase D2 Human genes 0.000 claims 1
- 102100037311 Serine/threonine-protein kinase D3 Human genes 0.000 claims 1
- 101710096799 Serine/threonine-protein kinase DCLK1 Proteins 0.000 claims 1
- 101710096798 Serine/threonine-protein kinase DCLK2 Proteins 0.000 claims 1
- 102100037705 Serine/threonine-protein kinase Nek4 Human genes 0.000 claims 1
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 claims 1
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 claims 1
- 102100030267 Serine/threonine-protein kinase PLK4 Human genes 0.000 claims 1
- 102100028954 Serine/threonine-protein kinase TAO3 Human genes 0.000 claims 1
- 108010039445 Stem Cell Factor Proteins 0.000 claims 1
- 101150052413 TNK2 gene Proteins 0.000 claims 1
- 102000005937 Tropomyosin Human genes 0.000 claims 1
- 108010030743 Tropomyosin Proteins 0.000 claims 1
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 claims 1
- 101710192735 Tyrosine-protein kinase receptor UFO Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000005441 aurora Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 239000003226 mitogen Substances 0.000 claims 1
- 230000000394 mitotic effect Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 239000011435 rock Substances 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
- 108010020246 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 Proteins 0.000 description 10
- 206010039491 Sarcoma Diseases 0.000 description 7
- 206010024612 Lipoma Diseases 0.000 description 4
- 206010016629 fibroma Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010007275 Carcinoid tumour Diseases 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 101000950687 Homo sapiens Mitogen-activated protein kinase 7 Proteins 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 201000004404 Neurofibroma Diseases 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 208000000035 Osteochondroma Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 208000028591 pheochromocytoma Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 208000001608 teratocarcinoma Diseases 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 206010073106 Bone giant cell tumour malignant Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 1
- 206010016935 Follicular thyroid cancer Diseases 0.000 description 1
- 208000000527 Germinoma Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000009164 Islet Cell Adenoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 229940124786 LRRK2 inhibitor Drugs 0.000 description 1
- IWMCPJZTADUIFX-UHFFFAOYSA-N LRRK2-IN-1 Chemical compound C=1C=C(NC=2N=C3N(C)C4=CC=CC=C4C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)N(CC1)CCC1N1CCN(C)CC1 IWMCPJZTADUIFX-UHFFFAOYSA-N 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000006876 Multiple Endocrine Neoplasia Type 2b Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 201000003115 germ cell cancer Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000002529 islet cell tumor Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000004593 malignant giant cell tumor Diseases 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000022102 pancreatic neuroendocrine neoplasm Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000006845 reticulosarcoma Diseases 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000009540 villous adenoma Diseases 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361802075P | 2013-03-15 | 2013-03-15 | |
| US61/802,075 | 2013-03-15 | ||
| PCT/US2014/030760 WO2014145909A2 (en) | 2013-03-15 | 2014-03-17 | Pyrimido-diazepinone compounds and methods of treating disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018111642A Division JP6553772B2 (ja) | 2013-03-15 | 2018-06-12 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| JP2019125063A Division JP2019206534A (ja) | 2013-03-15 | 2019-07-04 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016515537A JP2016515537A (ja) | 2016-05-30 |
| JP2016515537A5 true JP2016515537A5 (enExample) | 2019-03-28 |
| JP6553589B2 JP6553589B2 (ja) | 2019-07-31 |
Family
ID=51538565
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016503457A Active JP6553589B2 (ja) | 2013-03-15 | 2014-03-17 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| JP2018111642A Active JP6553772B2 (ja) | 2013-03-15 | 2018-06-12 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| JP2019125063A Pending JP2019206534A (ja) | 2013-03-15 | 2019-07-04 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018111642A Active JP6553772B2 (ja) | 2013-03-15 | 2018-06-12 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
| JP2019125063A Pending JP2019206534A (ja) | 2013-03-15 | 2019-07-04 | ピリミド−ジアゼピノン化合物および障害の治療方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (4) | US9676792B2 (enExample) |
| EP (4) | EP3670515B1 (enExample) |
| JP (3) | JP6553589B2 (enExample) |
| CA (1) | CA2902599C (enExample) |
| WO (1) | WO2014145909A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014145909A2 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
| EP3189051A1 (en) * | 2014-09-02 | 2017-07-12 | Pierre Fabre Médicament | Isoquinolinone derivatives useful in the treatment of cancer |
| CN104803914B (zh) * | 2015-03-05 | 2017-11-14 | 成都理工大学 | 作为Rho激酶抑制剂的六氢氮杂卓氧基苯甲酰胺类化合物 |
| EP3307069B1 (en) * | 2015-06-10 | 2021-08-04 | Hackensack University Medical Center | Use of telmisartan to prevent and treat graft versus host disease and other alloimmune and autoimmune diseases |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| US11214565B2 (en) | 2015-11-20 | 2022-01-04 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| MX387025B (es) * | 2016-03-04 | 2025-03-19 | Anhui New Star Pharmaceutical Dev Co Ltd | Compuestos de anillo de siete miembros de pirimidina |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| SG11201808106YA (en) * | 2016-03-25 | 2018-10-30 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| KR20180132812A (ko) * | 2016-04-07 | 2018-12-12 | 다나-파버 캔서 인스티튜트 인크. | 피리미도-디아제피논 키나아제 스캐폴드 화합물 및 ｐｉ3ｋ-매개된 장애의 치료 방법 |
| SMT202100699T1 (it) | 2016-06-16 | 2022-01-10 | Denali Therapeutics Inc | Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi |
| WO2018055503A1 (en) | 2016-09-20 | 2018-03-29 | Novartis Ag | Combination comprising a pd-1 antagonist and an fgfr4 inhibitor |
| AU2017346845B2 (en) * | 2016-10-18 | 2021-12-02 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders |
| SG11201903911UA (en) | 2016-11-02 | 2019-05-30 | Novartis Ag | Combinations of fgfr4 inhibitors and bile acid sequestrants |
| KR101923852B1 (ko) * | 2017-02-24 | 2018-11-29 | 재단법인 대구경북첨단의료산업진흥재단 | 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물 |
| US10298137B2 (en) * | 2017-03-10 | 2019-05-21 | Semiconductor Components Industries, Llc | Advanced frequency reduction of quasi-resonant converters |
| EP3728268A4 (en) * | 2017-12-22 | 2021-07-28 | Dana-Farber Cancer Institute, Inc. | NEK INHIBITORS AND METHODS OF USE |
| EP3775185A4 (en) * | 2018-04-13 | 2022-05-04 | The Regents Of The University Of California | DETECTION OF PHOSPHOKINASE SIGNATURES |
| EP3858819A4 (en) | 2018-09-30 | 2022-05-18 | Medshine Discovery Inc. | 3,9-DIAZASPIRO[5,5] UNDECAN COMPOUND AS FLT3 AND AXL INHIBITORS |
| CN111039944B (zh) * | 2018-10-12 | 2021-11-23 | 中国科学院合肥物质科学研究院 | Mst1激酶抑制剂及其用途 |
| CN109824678B (zh) * | 2019-03-20 | 2020-06-19 | 浙江大学 | 一种氮杂卓吲哚类生物碱及制备和抗疟疾用途 |
| WO2020206608A1 (en) | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| EP3965803B1 (en) | 2019-05-10 | 2025-08-20 | Dana-Farber Cancer Institute, Inc. | Small-molecule focal adhesion kinase (fak) inhibitors |
| EP3994132A1 (en) * | 2019-07-03 | 2022-05-11 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
| US20220280530A1 (en) * | 2019-08-08 | 2022-09-08 | Anhui Newstar Pharmaceutical Development Co., Ltd. | Prevention or treatment of diseases and disorders associated with tissue damage |
| KR102498531B1 (ko) * | 2020-06-29 | 2023-02-13 | 한국과학기술연구원 | 단백질 카이네이즈 trkc에 선택적인 억제제로서의 신규 피리미도디아제핀 유도체 |
| WO2022061019A1 (en) * | 2020-09-16 | 2022-03-24 | Collaborations Pharmaceuticals, Inc. | The antiviral drug tilorone is a potent and selective inhibitor of acetylcholinesterase |
| WO2022078350A1 (en) * | 2020-10-14 | 2022-04-21 | Ranok Therapeutics (Hangzhou) Co. Ltd. | Methods and compositions for targeted protein degradation |
| CN117088878A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
| EP4274567A1 (en) * | 2021-01-05 | 2023-11-15 | Sumitomo Pharma Oncology, Inc. | Forms and formulations of a tyrosine kinase non-receptor 1 (tnk1) inhibitor |
| CN121537408A (zh) | 2021-02-08 | 2026-02-17 | 上海复星医药产业发展有限公司 | 5，6-二氢噻吩并[3，4-h]喹唑啉类化合物 |
| TW202321244A (zh) * | 2021-07-26 | 2023-06-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| AR127170A1 (es) * | 2021-09-30 | 2023-12-27 | Crinetics Pharmaceuticals Inc | Antagonistas del receptor de la hormona paratiroidea (pth) y sus usos |
| CN114478539B (zh) * | 2022-02-09 | 2024-02-02 | 中国人民解放军海军军医大学 | 一种新型dclk1抑制剂及其制备方法和应用 |
| CN115877004B (zh) * | 2022-08-09 | 2024-12-20 | 重庆大学 | 一种taok3抑制剂以及taok3及其抑制剂在调控天然免疫系统中的应用 |
| CN116173040B (zh) * | 2022-08-23 | 2025-05-23 | 杭州天玑济世生物科技有限公司 | Xmd17109作为arih1激动剂的用途 |
| EP4509142A1 (en) | 2023-08-16 | 2025-02-19 | Ona Therapeutics S.L. | Fgfr4 as target in cancer treatment |
| CN121154824A (zh) * | 2025-11-19 | 2025-12-19 | 安徽省立医院(中国科学技术大学附属第一医院) | Nuak1作为生物标志物在骨质疏松临床诊断和预防中的应用及其试剂盒 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7622463B2 (en) | 2006-02-14 | 2009-11-24 | Vertex Pharmaceuticals Incorporated | Dihydrodiazepines useful as inhibitors of protein kinases |
| AU2008228303B2 (en) | 2007-03-22 | 2012-04-19 | Takeda Pharmaceutical Company Limited | Substituted pyrimidodiazepines useful as PLK1 inhibitors |
| PL2205603T3 (pl) * | 2007-09-28 | 2014-07-31 | Cyclacel Ltd | Pochodne pirymidyny jako inhibitory kinaz białkowych |
| EP3828185B1 (en) * | 2009-01-06 | 2024-11-20 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders |
| GB201205752D0 (en) | 2012-03-30 | 2012-05-16 | Cyclacel Ltd | Treatment |
| WO2014145909A2 (en) * | 2013-03-15 | 2014-09-18 | Dana-Farber Cancer Institute, Inc. | Pyrimido-diazepinone compounds and methods of treating disorders |
-
2014
- 2014-03-17 WO PCT/US2014/030760 patent/WO2014145909A2/en not_active Ceased
- 2014-03-17 EP EP20155968.9A patent/EP3670515B1/en active Active
- 2014-03-17 EP EP18174175.2A patent/EP3388436B1/en active Active
- 2014-03-17 CA CA2902599A patent/CA2902599C/en active Active
- 2014-03-17 US US14/775,897 patent/US9676792B2/en active Active
- 2014-03-17 EP EP20183712.7A patent/EP3738964A1/en active Pending
- 2014-03-17 JP JP2016503457A patent/JP6553589B2/ja active Active
- 2014-03-17 EP EP14764298.7A patent/EP2970317A4/en not_active Withdrawn
-
2017
- 2017-04-28 US US15/581,702 patent/US10189861B2/en active Active
-
2018
- 2018-06-12 JP JP2018111642A patent/JP6553772B2/ja active Active
- 2018-11-20 US US16/195,983 patent/US10457692B2/en active Active
-
2019
- 2019-07-04 JP JP2019125063A patent/JP2019206534A/ja active Pending
- 2019-09-13 US US16/570,490 patent/US10787461B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016515537A5 (enExample) | ||
| JP2018168169A5 (enExample) | ||
| JP7491914B2 (ja) | ＳＭＡＲＣＡ２及び／又はＳＭＡＲＣＡ４のディグレーダーとしてのタンパク質分解誘導キメラ（Ｐｒｏｔａｃ） | |
| CN114380799B (zh) | Cot调节剂及其使用方法 | |
| US12281099B2 (en) | Isoindolinone substituted indoles and derivatives as RAS inhibitors | |
| ES2921257T3 (es) | Nuevo derivado de imidazopiridina, procedimiento para prepararlo y composición farmacéutica que contiene el mismo como ingrediente activo para prevenir o tratar el cáncer | |
| ES2669423T3 (es) | 2-Amino-6-fluoro-N-(5-fluoro-4-(4-(4-(oxetan-3-il)piperazin-1-carbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-carboxamida como inhibidor de ATR quinasa | |
| RS64167B1 (sr) | Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori | |
| BR112021016132A2 (pt) | Novo derivado de pirido[3,4-d]pirimidin-8-ona tendo atividade inibitória da proteína quinase e composição farmacêutica para prevenir, aliviar ou tratar o câncer, que o compreende | |
| JP6896755B2 (ja) | エクソン２０挿入変異型ｅｇｆｒ選択的阻害剤 | |
| CL2017000420A1 (es) | Compuestos diaza-y triaza-triciclicos sustituidos con ciclohexil-etilo como antagonistas de indol-amina-2,3-dioxigenasa (ido) para el tratamiento de cáncer. | |
| JOP20190144A1 (ar) | إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز | |
| WO2013143466A1 (zh) | 作为欧若拉激酶抑制剂的取代嘧啶衍生物 | |
| MX391936B (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak | |
| WO2021104305A1 (zh) | 含氮多环类衍生物抑制剂、其制备方法和应用 | |
| BRPI0922801A2 (pt) | compostos | |
| US9845320B2 (en) | Benzothiazole or benzoxazole compounds as sumo activators | |
| JP2019512535A5 (enExample) | ||
| CN112789279B (zh) | 含三并环类衍生物抑制剂、其制备方法和应用 | |
| TW200804364A (en) | New compounds | |
| CN110546150B (zh) | 含吡唑基的三并环类衍生物、其制备方法和应用 | |
| JP2013516455A5 (enExample) | ||
| JPWO2019045036A1 (ja) | エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤 | |
| CL2016001739A1 (es) | Trece compuestos específicos derivados de 6,7,8,8a-tetrahidro-5h-imidazol1,5-a-piridin-1,3-diona, moduladores alostéricos positivos map del receptor metabotrópico del glutamato 4 mglur4 composiciones farmacológicas procedimiento de preparación útiles para el tratamiento del parkinson, ansiedad, emesis, trastorno obsesivo-compulsivo, autismo, neuroprotección, cáncer, depresión, esquizofrenia y diabetes tipo 2. | |
| CN109311901A (zh) | 嘧啶并-二氮杂卓酮激酶骨架化合物及治疗pi3k介导的病变的方法 |